Company intelligence / Profile preview
Lantern Pharma
Dallas, Texas, United Stateslanternpharma.com ↗
- Ownership
- Public · LTRN
- Employees
- ~24
- Development stage
- Phase 2
01
Overview
Lantern Pharma has three lead small molecule candidates—LP‑300, LP‑184, LP‑284—and an ADC program. LP‑300 is in global Phase 2 trials for NSCLC in never-smokers; preliminary U.S. data show an 86% clinical benefit rate and a 43% objective response rate. LP‑184 is advancing toward investigator-led studies for recurrent bladder cancer and shows synergy with anti-PD1 therapy in TNBC preclinical models. LP‑284 entered first-in-human Phase 1 trials for relapsed/refractory non-Hodgkin’s lymphoma as of March 2024. The company leverages its RADR® platform to identify responsive patient populations rapidly.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesAntibody-drug conjugates (ADC)
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Academic collaborations with MD Anderson Cancer Center; partnerships with hospitals/universities/non-profits globally to accelerate developmentOutlicensed program LP–100 to Oncology Venture/Eisai collaboration
04
Financials
- Market cap
- $7.9M
- Total revenue
- $0
- Enterprise value
- $624.2K
Beyond the preview
Go deeper on Lantern Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lantern Pharma.